NICE supports Roche’s blood cancer drug

As reported by Bloomberg, The National Institute for Health and Clinical Excellence has voiced it’s support for Roche’s MabThera drug, a medicine used for fight a common form of blood cancer.

The Institute supports the drugs use on patients suffering with follicular lymphoma who have previously responded to treatment with MabThera combined with chemotherapy.

Studies have shown that the drug can reduce the spread and growth of cancer by three to four years. MabThera is also approved for use in the treatment of rheumatoid arthritis and chronic lymphocytic leukaemia, as well as non-Hodgkins lymphoma.

Are you looking for your next role within the pharmaceutical industry? Click here to search our current pharmaceutical jobs.

Posted in: Industry News
CK Logo in place of featured image